A Strategic Turn from Obesity to Cancer

Episode Summary

Executive Summary: Amy Burroughs explains how Turns Pharmaceuticals pivoted from metabolic disease to CML after strong TERN-701 data suggested a potentially best-in-disease allosteric BCR-ABL inhibitor. She details the company’s focus on execution, FDA engagement, pivotal-trial planning, selective asset partnering, and building toward a broader oncology future while maintaining commercial discipline.

Main Topics: Leadership transition and company reset (Priority: 5/5): Burroughs describes joining after CEO Sen Sudaram’s death, filling a leadership void, respecting the existing culture, and steering the company into its next phase. Strategic pivot to CML (Priority: 5/5): Turns shifted resources away from obesity/metabolic disease because TERN-701 data emerged as far more compelling than the competitive landscape in metabolic disease. CML disease burden and unmet need (Priority: 5/5): The discussion explains how CML is treated today, why patients still face long-term drug burden and side effects, and why better tolerability matters even when survival is good. TERN-701 mechanism and differentiation (Priority: 5/5): TERN-701 is an allosteric BCR-ABL inhibitor that binds a different site than older TKIs, aiming for greater selectivity, efficacy, and improved tolerability, plus easier dosing with no food restrictions. Clinical data and development path (Priority: 4/5): Burroughs highlights strong early results, plans to select a dose with the FDA, and a path toward pivotal trials in second-line and potentially frontline settings. Capital raise, investor response, and partnering strategy (Priority: 4/5): She says investors rewarded the CML data with a large financing round, and that non-core metabolic assets may be licensed while the company keeps CML as the main priority. Commercial planning and future oncology pipeline (Priority: 3/5): Turns intends to commercialize TERN-701 itself while preparing early for access, payer, and positioning work, and it is also exploring additional oncology discovery opportunities.

Key Arguments: Turns’ strategic shift was data-driven rather than ideology-driven; as TERN-701’s profile improved, it became clear the asset had much greater potential than the metabolic programs. The CML market remains highly attractive because many patients must remain on therapy for life, and current drugs still have significant safety and tolerability limitations. An allosteric mechanism offers higher selectivity than first- and second-generation active-site inhibitors, which may reduce off-target toxicity and improve adherence. TERN-701 appears to raise the bar versus current CML options by combining strong molecular response rates with a notably clean safety profile. The company can advance TERN-701 with its existing capital, reducing financing risk and supporting an independent launch strategy. Turns will stay focused by deprioritizing non-core metabolic assets and potentially licensing them rather than diluting resources across too many programs. The company plans to build commercial readiness early, leveraging Burroughs’ commercial background while keeping the organization lean.

Data Points: Year Burroughs joined Turns: 2024 - She says she started in February 2024. Interim CEO gap: 2.5 months - The transcript notes a brief interim-CEO period before Burroughs took over. Patient failure on front-line CML therapy: 40% to 50% - Burroughs says many patients progress to another therapy due to efficacy, safety, or tolerability. Resistance mutations among heavily pretreated patients: About 15% - In phase 1 cardinal trial patients who failed 3+ therapies, only a minority had resistance mutations. Major molecular response with current best therapy: About 25% - In similar third-line-plus patients, the current benchmark was described as ~25%. Major molecular response with TERN-701: 75% - Early data at expansion doses showed 75% reached major molecular response. Typical fasting requirement for some therapies: 3 hours - TERN-701 can be taken without regard to food, unlike some therapies requiring fasting windows. Target dosing timeline for pivotal trial: Late 2026 to early 2027 - Burroughs expects dosing in a pivotal trial by then. Planned pivotal trial size: 250 or so patients - She compared it to the other allosteric’s third-line-plus study size. Capital raised: $748 million - She references an upsized public offering that provided funding through pivotal trials and launch. Stock level after 601 data: Below $7 - She says the stock may have dipped below this level after the phase 2 obesity data. Phase 2 601 readout date: October - The transcript states phase 2 results were reported in October and did not support further obesity development.

Pivotal Quotes: "we really followed the data" — Amy Burroughs: Explaining why Turns pivoted from metabolic disease to CML. "It really was a pretty easy decision to focus there" — Amy Burroughs: Describing the shift toward TERN-701 after the CML data strengthened. "we have really shown the ability to raise the bar to the next level on safety and efficacy" — Amy Burroughs: Summarizing TERN-701’s differentiation versus existing CML therapies.

Implications: Turns is positioning TERN-701 as a potentially category-leading CML drug with a credible path to pivotal trials and commercialization. The story also reflects a broader biotech lesson: follow the best data, stay focused, and use capital to build toward a differentiated launch.